Evogene (EVGN) Intangibles (2012 - 2025)
Evogene (EVGN) posted Intangibles of $12.0 million for Q1 2025, down 1.97% sequentially from $12.2 million in Q4 2024, and down 7.5% YoY from $12.9 million in Q1 2024.
Evogene (EVGN) Intangibles (2012 - 2025) Analysis & Trends
Evogene has reported Intangibles for 10 years, with the latest figure at $12.0 million in Q1 2025.
- Quarterly Intangibles fell 7.5% year-over-year to $12.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $12.0 million (down 7.5% YoY) and the FY2024 annual result came in at $12.2 million, down 30.11% from the prior year.
- Intangibles declined to $12.0 million in Q1 2025 per EVGN's latest filing, from $12.2 million in the prior quarter.
- Over five years, Intangibles peaked at $17.4 million in Q4 2021 and troughed at $12.0 million in Q1 2025.
- A 5-year average of $14.5 million and a median of $14.4 million in 2022 frame the typical range for Intangibles.
- The sharpest annual moves came in 2021 and 2024: Intangibles changed 0.0% in 2021, then slumped 30.11% in 2024.
- Over 5 years, Intangibles stood at $17.4 million in 2021, then changed by 0.0% to $17.4 million in 2022, then changed by 0.0% to $17.4 million in 2023, then sank by 30.11% to $12.2 million in 2024, then dropped by 1.97% to $12.0 million in 2025.
- According to Business Quant data, Intangibles over the past three periods registered $12.0 million, $12.2 million, and $12.4 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 11.96 Mn |
| Dec 31, 2024 | 12.20 Mn |
| Sep 30, 2024 | 12.44 Mn |
| Jun 30, 2024 | 12.69 Mn |
| Mar 31, 2024 | 12.92 Mn |
| Dec 31, 2023 | 17.45 Mn |
| Sep 30, 2023 | 13.41 Mn |
| Jun 30, 2023 | 13.66 Mn |
| Mar 31, 2023 | 13.90 Mn |
| Dec 31, 2022 | 17.45 Mn |
| Sep 30, 2022 | 14.39 Mn |
| Jun 30, 2022 | 14.63 Mn |
| Mar 31, 2022 | 14.87 Mn |
| Dec 31, 2021 | 17.45 Mn |
| Sep 30, 2021 | 15.44 Mn |
| Jun 30, 2021 | 15.68 Mn |
| Mar 31, 2021 | 15.91 Mn |
| Dec 31, 2020 | 17.45 Mn |
| Sep 30, 2020 | 16.37 Mn |
| Jun 30, 2020 | 16.61 Mn |